Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with transthyretin amyloid cardiomyopathy and/or receiving tafamidis prescriptions: A retrospective analysis of a Medicare cohort

BACKGROUND: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, life-threatening condition that mostly affects older persons. In May 2019, regulatory approval of tafamidis provided the first pharmacologic treatment of ATTR-CM. In the pivotal phase 3 Transthyretin Amyloidosis Cardiom...

Descripción completa

Detalles Bibliográficos
Autores principales: Roy, Anuja, Peterson, Andrew, Marchant, Nick, Alvir, Jose, Bhambri, Rahul, Bredl, Zach, Benjumea, Darrin, Kemner, Jason, Parasuraman, Bhash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372989/
https://www.ncbi.nlm.nih.gov/pubmed/35737856
http://dx.doi.org/10.18553/jmcp.2022.28.7.766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372989/
https://www.ncbi.nlm.nih.gov/pubmed/35737856
http://dx.doi.org/10.18553/jmcp.2022.28.7.766

Ejemplares similares